Precision BioSciences Announces Presentations at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy
24. April 2019 06:30 ET
|
Precision Biosciences
DURHAM, N.C., April 24, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS® genome...
Precision BioSciences Announces Dosing of First Patient in Off-The-Shelf CAR T Cell Therapy Phase 1/2a Clinical Trial
17. April 2019 05:30 ET
|
Precision Biosciences
DURHAM, N.C., April 17, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS® genome...
Precision BioSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
01. April 2019 16:05 ET
|
Precision Biosciences
DURHAM, N.C., April 01, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS genome...
Precision BioSciences Announces Pricing of Initial Public Offering
27. März 2019 17:50 ET
|
Precision Biosciences
DURHAM, N.C., March 27, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS genome...